1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Gates Commits $89m To Novavax After Maternal RSV Vaccine Success

 
• By Mandy Jackson

Now that Novavax Inc.'s respiratory syncytial virus (RSV) vaccine has succeeded in a Phase II clinical trial in pregnant women, the Bill & Melinda Gates Foundation has committed up to $89m to help the company fund a massive Phase III trial that will include sites in developing countries.

Now that Novavax Inc.'s respiratory syncytial virus (RSV) vaccine has succeeded in a Phase II clinical trial in pregnant women, the Bill & Melinda Gates Foundation has committed up to $89m to help the company fund a massive Phase III trial that will include sites in developing countries.

Gaithersburg, Maryland-based Novavax revealed on Sept. 29 that its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F vaccine) generated significant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.